Clinical trial
Natalizumab Temporary Discontinuation Study
NCT02775110 is registered in ClinicalTrials.gov with University at Buffalo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Natalizumab Temporary Discontinuation Study
- Lead sponsor
- University at Buffalo
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- March 31, 2014
- Enrollment
- 50 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.